Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach

Rheumatic Disease Clinics of North America

Volumn 32, Issue 4, 2006, Pages 733-757

  Devogelaer, Jean Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIDIOL 1 MONOOXYGENASE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; DEFLAZACORT; DIHYDROTACHYSTEROL; ETIDRONIC ACID; GLUCOCORTICOID; METHYLPREDNISOLONE; NANDROLONE DECANOATE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PRASTERONE; PREDNISONE; RISEDRONIC ACID; TAMOXIFEN; TIBOLONE; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG INDICATION; FLUID RETENTION; FRACTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCORTISOLISM; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE PAIN; LIPID BLOOD LEVEL; MULTIPLE CYCLE TREATMENT; MYOPATHY; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN ATROPHY; SYSTEMATIC REVIEW; TRUNCAL OBESITY; ADULT; BONE; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PATHOPHYSIOLOGY;

ADULT; BONE AND BONES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 34247202629     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.09.001     Document Type: Review

References (152)

1. Hench P.S., Kendall E.C., Slocumb C.H., et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Preliminary report. Proc Staff Meet Mayo Clin 24 8 (1949) 181-197
2. Howell D.S., and Ragan C. The course of rheumatoid arthritis during four years of induced hyperadrenalism (IHA). Medicine (Baltimore) 35 2 (1956) 83-119
3. Kanis J.A., Johansson H., Oden A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 6 (2004) 893-899
4. van Staa T.P., Leufkens H.G.M., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 6 (2000) 993-1000
5. Curtis J.R., Westfall A.O., Allison J.J., et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52 8 (2005) 2485-2494
6. van Staa T.P., Cooper C., Leufkens H.G.M., et al. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18 5 (2003) 913-918
7. Hahn T.J., Boisseau V.C., and Avioli L.V. Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 39 2 (1974) 274-282
8. Nagant de Deuxchaisnes C., Devogelaer J.P., Esselinckx W., et al. The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry. Adv Exp Med Biol 171 (1984) 209-239
9. Maldague B., Malghem J., and Nagant de Deuxchaisnes C. Radiological aspects of glucocorticoid-induced bone disease. Adv Exp Med Biol 171 (1984) 155-190
10. Reid I.R., Evans M.C., Wattie D.J., et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int 2 2 (1992) 103-105
11. Albright F. Cushing's syndrome. Harvey Lect 38 (1942) 123-186
12. Cooper M.S., Rabbitt E.H., Goddard P.E., et al. Osteoblastic 11 β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17 6 (2002) 979-986
13. Devogelaer J.P., Huaux J.P., Dufour J.P., et al. Bone-sparing action of deflazacort versus equipotent doses of prednisone: a double-blind study in males with rheumatoid arthritis. In: Christiansen C., Johansen J.S., and Riis B.J. (Eds). Osteoporosis 1987 (1987), Norhaven A/S, Viborg, Denmark 1014-1015
14. Olgaard K., Storm T., van Wowern N., et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 50 6 (1992) 490-497
15. Gray R.E.S., Doherty S.M., Galloway J., et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 34 3 (1991) 287-295
16. Cacoub P., Chemlal K., Khalifa P., et al. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol 28 11 (2001) 2474-2479
17. Richy F., Bousquet J., Ehrlich G.E., et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 14 3 (2003) 179-190
18. Frediani B., Falsetti P., Bisogno S., et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 31 6 (2004) 1083-1087
19. Dovio A., Perazzolo L., Osella G., et al. Immediate fall of bone formation and transient increase in bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89 10 (2004) 4923-4928
20. van Staa T.P., Leufkens H.G.M., Abenhaim L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 39 12 (2000) 1383-1389
21. van Staa T.P., Laan R.F., Barton I.P., et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48 11 (2003) 3224-3229
22. Reid D.M., Kennedy N.S.J., Smith M.A., et al. Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment. BMJ 285 6338 (1982) 330-332
23. Wolthers O.D., and Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. BMJ 301 6744 (1990) 145-148
24. Leonard M.B., and Zemel B.S. Pediatric gastroenterology and nutrition. Current concepts in pediatric bone disease. Pediatr Clin North Am 49 1 (2002) 143-173
25. Boot A.M., de Jongste J.C., Verberne A.A.P.H., et al. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Pediatr Pulmonol 24 6 (1997) 379-384
26. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res 58 Suppl 1 (2002) 33-38
27. Saville P.D., and Kharmosh O. Osteoporosis of rheumatoid arthritis: influence of age, sex and corticosteroids. Arthritis Rheum 10 5 (1967) 423-430
28. Jardinet D., Lefèbvre C., Depresseux G., et al. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 39 4 (2000) 389-392
29. Reid D.M., Hughes R.A., Laan R.F.J.M., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15 6 (2000) 1006-1013
30. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67 4 (2000) 277-285
31. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44 1 (2001) 202-211
32. Reid D.M., Adami S., Devogelaer J.-P., et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69 4 (2001) 242-247
33. Prummel M.F., Wiersinga W.M., Lips P., et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72 2 (1991) 382-386
34. Kozower M., Veatch L., and Kaplan M.M. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. J Clin Endocrinol Metab 38 3 (1974) 407-412
35. Stevens A., Ray D.W., Zeggini E., et al. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J Clin Endocrinol Metab 89 2 (2004) 892-897
36. Fucik R.F., Kukreja S.C., Hargis G.K., et al. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 40 1 (1975) 152-155
37. Bressot C., Meunier P.J., Chapuy M.C., et al. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Relat Res 1 (1979) 303-311
38. Morris H.A., Need A.G., O'Loughlin P.D., et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 46 5 (1990) 305-308
39. Suzuki Y., Ichikawa Y., Saito E., et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32 2 (1983) 151-156
40. Paz-Pacheco E., El-Hajj Fuleihan G., and Leboff M.S. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res 10 11 (1995) 1713-1718
41. Silve C., Fritsch J., Grosse B., et al. Corticosteroid-induced changes in the responsiveness of human osteoblast-like cells to parathyroid hormone. Bone Miner 6 1 (1989) 65-75
42. Rodan S.B., Fischer M.K., Egan J.J., et al. The effect of dexamethasone on parathyroid hormone stimulation of adenylate cyclase in ROS 17/2.8 cells. Endocrinology 115 3 (1984) 951-958
43. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 10 (1999) 4382-4389
44. Sasaki N., Kusano E., Ando Y., et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 16 3 (2001) 479-482
45. von Tirpitz C., Epp S., Klaus J., et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 15 11 (2003) 1165-1170
46. Godschalk M.F., and Downs R.W. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 3 1 (1988) 113-115
47. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 2 (1998) 274-282
48. Schorlemmer S., Ignatius A., Claes L., et al. Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheep. Bone 37 4 (2005) 491-496
49. Lane N.E. New observations on bone fragility with glucocorticoid treatment. Results from an in vivo animal model. J Musculoskelet Neuronal Interact 5 4 (2005) 331-332
50. Meunier P., Bernard J., and Vignon G. La mesure de l'élargissement périostéocytaire appliquée au diagnostic des hyperparathyroïdies. Path Biol (Paris) 19 7-8 (1971) 371-378
51. Montecucco C., Caporali R., Caprotti P., et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 19 12 (1992) 1895-1900
52. Devogelaer J.P., Crabbé J., and Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. BMJ 294 6575 (1987) 798-800
53. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290 13 (2003) 1729-1738
54. MacAdams M.R., White R.H., and Chipps B.E. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 104 5 (1986) 648-651
55. Hampson G., Bhargava N., Cheung J., et al. Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. Metabolism 51 11 (2002) 1458-1462
56. Riggs B.L., Khosla S., and Melton III L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13 5 (1998) 763-773
57. Crawford B.A.L., Liu P.Y., Kean M.T., et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88 7 (2003) 3167-3176
58. Dempster D.W. Perspectives. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4 2 (1989) 137-141
59. Stellon A.J., Webb A., and Compston J.E. Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 29 (1988) 378-384
60. Aaron J.E., Francis R.M., Peacock M., et al. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop 243 (1989) 294-305
61. Chappard D., Legrand E., Basle M.F., et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11 5 (1996) 676-685
62. Dalle Carbonare L., Arlot M.E., Chavassieux P.M., et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16 1 (2001) 97-103
63. Lane N.E., Yao W., Balooch M., et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21 3 (2006) 466-476
64. Vedi S., Elkin S.L., and Compston J.E. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif Tissue Int 77 (2005) 79-83
65. Pocock N.A., Eisman J.A., Dunstan C.R., et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 107 (1987) 319-323
66. Laan R.F.J.M., van Riel P.L.C.M., van de Putte L.B.A., et al. Low-dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 119 (1993) 963-968
67. Abadie E.C., Devogelaer J.-P., Ringe J.D., et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum 35 (2005) 1-4
68. Bone and Tooth Society of Great Britain, Royal College of Physicians, and National Osteoporosis Society. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis (2003), Royal College of Physicians, London
69. Sambrook P.N. How to prevent steroid induced osteoporosis. Ann Rheum Dis 64 (2005) 176-178
70. Holick M.F. Vitamin D. Clinical Review in Bone and Mineral Metabolism 1 3/4 (2002) 181-207
71. Cordier P., Decruynaere C., and Devogelaer J.P. Bone mineral density in postransplantation patients: effects of physical activity. Transplant Proc 32 (2000) 411-414
72. Mahony J.F., Savdie E., Caterson R.J., et al. The natural history of cadaveric renal allografts beyond ten years. Transplant Proc 18 (1986) 135-137
73. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39 11 (1996) 1791-1801
74. Adler R.A., and Hochberg M.C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of Veterans Affairs. Arch Intern Med 163 21 (2003) 2619-2624
75. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. London: Royal College of Physicians; 2002. Available at =http://www.rcplondon.ac.uk/pubs/brochure.aspx?e=89. Accessed October 5, 2006.
76. Devogelaer J.P., Goemaere S., Boonen S., et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17 1 (2006) 8-19
77. Gluck O.S., Murphy W.A., Hahn T.J., et al. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 24 7 (1981) 892-898
78. Rüegsegger P., Medici T.C., and Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 25 (1983) 615-620
79. Avgerinos P.C., Cutler G.B., Tsokos G.C., et al. Dissociation between cortisol and adrenal androgen secretion in patients receiving alternate day prednisone therapy. J Clin Endocrinol Metab 65 (1987) 24-29
80. van Staa T.P., Leufkens H.G.M., and Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16 (2001) 581-588
81. Loftus J., Allen R., Hesp R., et al. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. Pediatrics 88 (1991) 428-436
82. David J., Loftus J., Hesp R., et al. Spinal and somatic growth in patients with juvenile chronic arthritis treated for up to 2 years with deflazacort. Clin Exp Rheumatol 10 6 (1992) 621-624
83. Devogelaer J.P., Manicourt D.H., and Boutsen Y. Glucocorticoid-induced osteoporosis: prevention and treatment. Curr Top Ster Res 4 (2004) 217-226
84. Devogelaer J.-P., and Gennari C. Deflazacort in giant cell arteritis. J Rheumatol 29 10 (2002) 2244
85. Sambrook P.N. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 15 9 (2000) 1645-1649
86. 2, calcium phosphate and sodium fluoride administration. Clin Endocrinol (Oxf) 16 4 (1982) 409-415
87. Worth H., Stammen D., and Keck E. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. Am J Respir Crit Care Med 150 2 (1994) 394-397
88. Vogelsang H., Ferenci P., Resch H., et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7 7 (1995) 605-614
89. Bernstein C.N., Seeger L.L., Anton P.A., et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 10 5 (1996) 777-786
90. Buckley L.M., Leib E.S., Cartularo K.S., et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125 12 (1996) 961-968
91. Adachi J.D., Bensen W.G., Bianchi F., et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23 6 (1996) 995-1000
92. Bijlsma J.W.J., Raymakers J.A., Mosch C., et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 6 2 (1988) 113-119
93. Di Munno O., Beghe F., Favini P., et al. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 8 2 (1989) 202-207
94. Devogelaer J.P., Esselinckx W., and Nagant de Deuxchaisnes C. Calcidiol protects bone mass in rheumatoid arthritis patients treated by low dose glucocorticoids. In: Norman A.W., Bouillon R., and Thomasset M. (Eds). Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications (1994), Walter de Gruyter, Berlin 855-856
95. Talalaj M., Gradowska L., Marcinowska-Suchowierska E., et al. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 28 6 (1996) 3485-3487
96. Garcia-Delgado I., Prieto S., Gil-Fraguas L., et al. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 60 2 (1997) 155-159
97. Dykman T.R., Haralson K.M., Gluck O.S., et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 27 12 (1984) 1336-1343
98. Sambrook P., Birmingham J., Kelly P., et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328 24 (1993) 1747-1752
99. Sambrook P., Henderson N.K., Keogh A., et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15 9 (2000) 1818-1824
100. Henderson K., Eisman J., Keogh A., et al. Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 16 3 (2001) 565-571
101. 3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment: a double blind controlled study. Clin Endocrinol (Oxf) 19 2 (1983) 265-273
102. Reginster J.Y., Kuntz D., Verdickt W., et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9 1 (1999) 75-81
103. Ringe J.D., Cöster A., Meng T., et al. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65 4 (1999) 337-340
104. Amin S., LaValley M.P., Simms R.W., et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42 8 (1999) 1740-1751
105. Amin S., Lavalley M.P., Simms R.W., et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17 8 (2002) 1512-1526
106. Lukert B.P., Johnson B.E., and Robinson R.G. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 7 9 (1992) 1063-1069
107. Hall G.M., Daniels M., Doyle D.V., et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37 10 (1994) 1499-1505
108. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized, controlled trial. JAMA 288 3 (2002) 321-333
109. Cummings S.R. LIFT study is discontinued. BMJ 332 7542 (2006) 667
110. Fentiman I.S., Saad Z., Caleffi M., et al. Tamoxifen protects against steroid-induced bone loss. Eur J Cancer 28 2/3 (1992) 684-685
111. Grecu E.O., Weinshelbaum A., and Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 46 5 (1990) 294-299
112. Mease P.J., Ginzler E.M., Gluck O.S., et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 32 (2005) 616-621
113. Cranney A., Welch V., Adachi J.D., et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis (review). The Cochrane Collaboration. The Cochrane Library I (2005) 1-31
114. Ringe J.-D., and Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33 (1987) 35-39
115. Böhning W., Ringe J.D., Welzel D., et al. Intranasales lachsalcatonin zur prophylaxe des knochenmineral-verkustes bei steroid-bedürftigen chronisch-obstruktiven atemwegserkrankunge. Arzneim-Forsch Drug Res 40 II (1990) 1000-1003
116. Luengo M., Picado C., Del Rio L., et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis 142 (1990) 104-107
117. Luengo M., Pons F., Martinez de Osaba M.J., et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 49 11 (1994) 1099-1102
118. Emkey R., Reading W., Procaccini R., the Steroid Induced Osteoporosis Study Group, et al. The effect of calcitonin on bone mass in steroid-induced osteoporosis. Arthritis Rheum 37 Suppl 9 (1994) S183
119. Healey J.H., Paget S.A., Williams-Russo P., et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 58 (1996) 73-80
120. Kotaniemi A., Piirainen H., Paimela L., et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?. J Rheumatol 23 (1996) 1875-1879
121. Adachi J.D., Bensen W.G., Bell M.J., et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36 (1997) 255-259
122. Mulder H., and Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33 (1994) 348-350
123. Struys A., Snelder A.A., and Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99 3 (1995) 235-242
124. Van Cleemput J., Daenen W., Geusens P., et al. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation 61 (1996) 1495-1499
125. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337 (1997) 382-387
126. Skingle S.J., Moore D.J., and Crisp A.J. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. Int J Clin Pract 51 (1997) 364-367
127. Wolfhagen F.H.J., Van Buuren H.R., den Ouden J.W., et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 26 (1997) 325-330
128. Pitt P., Li F., Todd P., et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 53 (1998) 351-356
129. Roux C., Oriente P., Laan R., et al., for the Ciblos Study Group. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83 (1998) 1128-1133
130. Jenkins E.A., Walker-Bone K.E., Wood A., et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 28 (1999) 152-156
131. Herrala J., Puolijoki H., Liippo K., et al. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 22 5 (1998) 577-582
132. Frediani B., Falsetti P., Baldi F., et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 33 (2003) 575-581
133. Boutsen Y., Jamart J., Esselinckx W., and Devogelaer J.P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16 (2001) 104-112
134. Nzeusseu Toukap A., Depresseux G., Devogelaer J.P., et al. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss im premenopausal connective tissue disease (mainly lupus) patients. Lupus 14 (2005) 517-520
135. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339 (1998) 292-299
136. Eastell R., Devogelaer J.P., Peel N.F.A., et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11 (2000) 331-337
137. Shane E., Addesso V., Namerow P.B., et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350 (2004) 767-776
138. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309-2318
139. Devogelaer J.P., Burckhardt P., Meunier P., et al. Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis. Osteoporos Int 17 Suppl 1 (2006) S14
140. Rico H., Cabranes J.A., Hernandez E.R., et al. Reversion of the steroid-induced decrease of serum osteocalcin with sodium fluoride. Clin Rheumatol 10 (1991) 10-12
141. Greenwald M., Brandli D., Spector S., et al. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporos Int 2 (1992) 303-304
142. Meys E., Terreaux-Duvert F., Beaume-Six T., et al. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporos Int 3 (1993) 322-329
143. Rizzoli R., Chevalley T., Slosman D.O., et al. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int 5 (1995) 39-46
144. Guaydier-Souquières G., Kotzki P.O., Sabatier J.P., et al. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int 6 (1996) 171-177
145. Lippuner K., Haller B., Casez J.P., et al. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticoids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 22 (1996) 207-213
146. Nagant de Deuxchaisnes C., and Devogelaer J.P. Restorative therapy of osteoporosis. In: Bröll H., and Dambacher M.A. (Eds). Osteoporosis: a guide to diagnosis and treatment Volume 18 (1996), Karger, Basel (Switzerland) 207-264
147. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102 (1998) 1627-1633
148. Lane N.E., Sanchez S., Modin G.W., et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15 (2000) 944-951
149. Buxton E.C., Yao W., and Lane N.E. Changes in serum receptor activator of nuclear factor κBligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 89 7 (2004) 3332-3336
150. Rhen T., and Cidlowski J.A. Mechanisms of disease. Antiinflammatory action of glucocortioids-new mechanisms for old drugs. N Engl J Med 353 16 (2005) 1711-1723
151. Durez P.B., Depresseux G., Houssiau F.A., and Devogelaer J. Follow up of DXA bone mineral density measurement in severe and refractory rheumatoid arthritis (RA) treated with infliximab (IFX). Ann Rheum Dis 63 Suppl 1 (2004) 96
152. Goffin E., Devogelaer J.P., Depresseux G., et al. Evaluation of bone mineral density after renal transplantation under a tracolimus-based immunosuppression: a pilot study. Clin Nephrol 59 3 (2003) 190-195